Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
BRAF V600 Mutations in Solid Tumors Market Segmentation
1. Executive Summary
2. Global BRAF V600 Mutations in Solid Tumors Market Introduction
2.1. Global BRAF V600 Mutations in Solid Tumors Market - Taxonomy
2.2. Global BRAF V600 Mutations in Solid Tumors Market - Definitions
2.2.1. Tumor Type
2.2.2. Treatment Method
2.2.3. BRAF Mutation Status
2.2.4. End-User
2.2.5. Region
3. Global BRAF V600 Mutations in Solid Tumors Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global BRAF V600 Mutations in Solid Tumors Market By Tumor Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Melanoma
4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Colorectal Cancer
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Lung Cancer
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Thyroid Cancer
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
4.5. Other Solid Tumor Types
4.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.5.3. Market Opportunity Analysis
5. Global BRAF V600 Mutations in Solid Tumors Market By Treatment Method, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Targeted Therapies
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immunotherapy
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Combination Therapies
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Surgery
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Radiation Therapy
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global BRAF V600 Mutations in Solid Tumors Market By BRAF Mutation Status, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. BRAF V600E
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. BRAF V600K
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Other BRAF Mutations
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global BRAF V600 Mutations in Solid Tumors Market By End-User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Treatment Centers
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Clinics
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Research Institutions
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global BRAF V600 Mutations in Solid Tumors Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. MEA
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global BRAF V600 Mutations in Solid Tumors Market - Opportunity Analysis Index, By Treatment Method, Tumor Type, BRAF Mutation Status, End-User, , , , and Region, 2023-2029
9. North America BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Melanoma
9.1.2. Colorectal Cancer
9.1.3. Lung Cancer
9.1.4. Thyroid Cancer
9.1.5. Other Solid Tumor Types
9.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Targeted Therapies
9.2.2. Chemotherapy
9.2.3. Immunotherapy
9.2.4. Combination Therapies
9.2.5. Surgery
9.2.6. Radiation Therapy
9.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. BRAF V600E
9.3.2. BRAF V600K
9.3.3. Other BRAF Mutations
9.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1. Hospitals
9.4.2. Cancer Treatment Centers
9.4.3. Clinics
9.4.4. Research Institutions
9.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.5.1. USA
9.5.2. Canada
10. Europe BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Melanoma
10.1.2. Colorectal Cancer
10.1.3. Lung Cancer
10.1.4. Thyroid Cancer
10.1.5. Other Solid Tumor Types
10.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Targeted Therapies
10.2.2. Chemotherapy
10.2.3. Immunotherapy
10.2.4. Combination Therapies
10.2.5. Surgery
10.2.6. Radiation Therapy
10.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. BRAF V600E
10.3.2. BRAF V600K
10.3.3. Other BRAF Mutations
10.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1. Hospitals
10.4.2. Cancer Treatment Centers
10.4.3. Clinics
10.4.4. Research Institutions
10.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
11. Asia Pacific BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Melanoma
11.1.2. Colorectal Cancer
11.1.3. Lung Cancer
11.1.4. Thyroid Cancer
11.1.5. Other Solid Tumor Types
11.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Targeted Therapies
11.2.2. Chemotherapy
11.2.3. Immunotherapy
11.2.4. Combination Therapies
11.2.5. Surgery
11.2.6. Radiation Therapy
11.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. BRAF V600E
11.3.2. BRAF V600K
11.3.3. Other BRAF Mutations
11.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1. Hospitals
11.4.2. Cancer Treatment Centers
11.4.3. Clinics
11.4.4. Research Institutions
11.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.5.1. China
11.5.2. Japan
11.5.3. South Korea
11.5.4. India
11.5.5. Rest of APAC
12. Latin America BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1. Melanoma
12.1.2. Colorectal Cancer
12.1.3. Lung Cancer
12.1.4. Thyroid Cancer
12.1.5. Other Solid Tumor Types
12.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1. Targeted Therapies
12.2.2. Chemotherapy
12.2.3. Immunotherapy
12.2.4. Combination Therapies
12.2.5. Surgery
12.2.6. Radiation Therapy
12.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1. BRAF V600E
12.3.2. BRAF V600K
12.3.3. Other BRAF Mutations
12.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1. Hospitals
12.4.2. Cancer Treatment Centers
12.4.3. Clinics
12.4.4. Research Institutions
12.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Argentina
12.5.4. Rest of Latin America
13. MEA BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1. Melanoma
13.1.2. Colorectal Cancer
13.1.3. Lung Cancer
13.1.4. Thyroid Cancer
13.1.5. Other Solid Tumor Types
13.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1. Targeted Therapies
13.2.2. Chemotherapy
13.2.3. Immunotherapy
13.2.4. Combination Therapies
13.2.5. Surgery
13.2.6. Radiation Therapy
13.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1. BRAF V600E
13.3.2. BRAF V600K
13.3.3. Other BRAF Mutations
13.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1. Hospitals
13.4.2. Cancer Treatment Centers
13.4.3. Clinics
13.4.4. Research Institutions
13.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Roche
14.2.2. Pfizer
14.2.3. Novartis
14.2.4. Bristol-Myers Squibb
14.2.5. Eli Lilly and Company
14.2.6. Debiopharm Group
14.2.7. Bayer
14.2.8. AstraZeneca
14.2.9. Exelixis
14.2.10. Daiichi Sankyo
15. Research Methodology
16. Key Assumptions and Acronyms
2. Global BRAF V600 Mutations in Solid Tumors Market Introduction
2.1. Global BRAF V600 Mutations in Solid Tumors Market - Taxonomy
2.2. Global BRAF V600 Mutations in Solid Tumors Market - Definitions
2.2.1. Tumor Type
2.2.2. Treatment Method
2.2.3. BRAF Mutation Status
2.2.4. End-User
2.2.5. Region
3. Global BRAF V600 Mutations in Solid Tumors Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global BRAF V600 Mutations in Solid Tumors Market By Tumor Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Melanoma
4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Colorectal Cancer
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Lung Cancer
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Thyroid Cancer
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
4.5. Other Solid Tumor Types
4.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.5.3. Market Opportunity Analysis
5. Global BRAF V600 Mutations in Solid Tumors Market By Treatment Method, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Targeted Therapies
5 1 1 Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immunotherapy
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Combination Therapies
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Surgery
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Radiation Therapy
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global BRAF V600 Mutations in Solid Tumors Market By BRAF Mutation Status, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. BRAF V600E
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. BRAF V600K
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Other BRAF Mutations
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global BRAF V600 Mutations in Solid Tumors Market By End-User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Treatment Centers
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Clinics
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Research Institutions
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global BRAF V600 Mutations in Solid Tumors Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. MEA
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global BRAF V600 Mutations in Solid Tumors Market - Opportunity Analysis Index, By Treatment Method, Tumor Type, BRAF Mutation Status, End-User, , , , and Region, 2023-2029
9. North America BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Melanoma
9.1.2. Colorectal Cancer
9.1.3. Lung Cancer
9.1.4. Thyroid Cancer
9.1.5. Other Solid Tumor Types
9.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Targeted Therapies
9.2.2. Chemotherapy
9.2.3. Immunotherapy
9.2.4. Combination Therapies
9.2.5. Surgery
9.2.6. Radiation Therapy
9.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. BRAF V600E
9.3.2. BRAF V600K
9.3.3. Other BRAF Mutations
9.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1. Hospitals
9.4.2. Cancer Treatment Centers
9.4.3. Clinics
9.4.4. Research Institutions
9.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.5.1. USA
9.5.2. Canada
10. Europe BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Melanoma
10.1.2. Colorectal Cancer
10.1.3. Lung Cancer
10.1.4. Thyroid Cancer
10.1.5. Other Solid Tumor Types
10.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Targeted Therapies
10.2.2. Chemotherapy
10.2.3. Immunotherapy
10.2.4. Combination Therapies
10.2.5. Surgery
10.2.6. Radiation Therapy
10.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. BRAF V600E
10.3.2. BRAF V600K
10.3.3. Other BRAF Mutations
10.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1. Hospitals
10.4.2. Cancer Treatment Centers
10.4.3. Clinics
10.4.4. Research Institutions
10.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
11. Asia Pacific BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Melanoma
11.1.2. Colorectal Cancer
11.1.3. Lung Cancer
11.1.4. Thyroid Cancer
11.1.5. Other Solid Tumor Types
11.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Targeted Therapies
11.2.2. Chemotherapy
11.2.3. Immunotherapy
11.2.4. Combination Therapies
11.2.5. Surgery
11.2.6. Radiation Therapy
11.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. BRAF V600E
11.3.2. BRAF V600K
11.3.3. Other BRAF Mutations
11.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1. Hospitals
11.4.2. Cancer Treatment Centers
11.4.3. Clinics
11.4.4. Research Institutions
11.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.5.1. China
11.5.2. Japan
11.5.3. South Korea
11.5.4. India
11.5.5. Rest of APAC
12. Latin America BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1. Melanoma
12.1.2. Colorectal Cancer
12.1.3. Lung Cancer
12.1.4. Thyroid Cancer
12.1.5. Other Solid Tumor Types
12.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1. Targeted Therapies
12.2.2. Chemotherapy
12.2.3. Immunotherapy
12.2.4. Combination Therapies
12.2.5. Surgery
12.2.6. Radiation Therapy
12.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1. BRAF V600E
12.3.2. BRAF V600K
12.3.3. Other BRAF Mutations
12.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1. Hospitals
12.4.2. Cancer Treatment Centers
12.4.3. Clinics
12.4.4. Research Institutions
12.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Argentina
12.5.4. Rest of Latin America
13. MEA BRAF V600 Mutations in Solid Tumors Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Tumor Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1. Melanoma
13.1.2. Colorectal Cancer
13.1.3. Lung Cancer
13.1.4. Thyroid Cancer
13.1.5. Other Solid Tumor Types
13.2. Treatment Method Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1. Targeted Therapies
13.2.2. Chemotherapy
13.2.3. Immunotherapy
13.2.4. Combination Therapies
13.2.5. Surgery
13.2.6. Radiation Therapy
13.3. BRAF Mutation Status Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1. BRAF V600E
13.3.2. BRAF V600K
13.3.3. Other BRAF Mutations
13.4. End-User Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1. Hospitals
13.4.2. Cancer Treatment Centers
13.4.3. Clinics
13.4.4. Research Institutions
13.5. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Roche
14.2.2. Pfizer
14.2.3. Novartis
14.2.4. Bristol-Myers Squibb
14.2.5. Eli Lilly and Company
14.2.6. Debiopharm Group
14.2.7. Bayer
14.2.8. AstraZeneca
14.2.9. Exelixis
14.2.10. Daiichi Sankyo
15. Research Methodology
16. Key Assumptions and Acronyms
• Roche
• Pfizer
• Novartis
• Bristol-Myers Squibb
• Eli Lilly and Company
• Debiopharm Group
• Bayer
• AstraZeneca
• Exelixis
• Daiichi Sankyo
• Pfizer
• Novartis
• Bristol-Myers Squibb
• Eli Lilly and Company
• Debiopharm Group
• Bayer
• AstraZeneca
• Exelixis
• Daiichi Sankyo